Tioconazole
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
Tioconazole: From Superficial Fungal Infections to Vulvovaginitis
One-Sentence Summary
Tioconazole is an imidazole-class topical antifungal, historically used to treat superficial fungal infections such as vaginal candidiasis and dermatophytosis. The TxGNN model predicts it may also be effective for Vulvovaginitis, with 2 clinical trials and 20 publications currently supporting this direction, although none of the registered trials test tioconazole itself directly.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Superficial fungal infections (vaginal candidiasis, dermatophytosis) — per literature evidence (PMID 3510114); no formal UK licence text is available |
| Predicted New Indication | Vulvovaginitis |
| TxGNN Prediction Score | 99.23% |
| Evidence Level | L1 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known information from the associated literature, tioconazole is an imidazole-class antifungal agent with broad-spectrum activity against dermatophytes and yeasts, and some activity against Gram-positive bacteria and trichomonads (PMID 3510114). Its efficacy in superficial mycoses, including vaginal candidiasis, has been well documented in numerous open-label and randomised comparative studies from the 1980s onward.
Vulvovaginitis is a symptom complex most commonly caused by Candida species (candidal vulvovaginitis), bacterial vaginosis, or Trichomonas vaginalis infection. Since tioconazole’s established antifungal spectrum directly targets Candida, and candidal infection is the leading cause of vulvovaginitis, the TxGNN prediction aligns closely with the drug’s known pharmacology rather than representing an unrelated repositioning.
This mechanistic overlap is further reinforced by historical clinical evidence: several randomised, double-blind, and open comparative trials directly compared tioconazole with other azoles (clotrimazole, econazole, miconazole) and with oral ketoconazole in vaginal candidiasis, consistently reporting comparable cure rates. This body of evidence, while predating modern trial registries, provides a reasonable basis for treating vulvovaginitis as a mechanistically and clinically coherent extension of tioconazole’s original use.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT03839875 | Phase 4 | Completed | 116 | Open-label, single-arm study of Gynomax® XL ovule in trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis and mixed vaginal infections; drug identity relative to tioconazole not confirmed |
| NCT06056947 | Phase 3 | Completed | 577 | Randomised, three-arm study comparing new fenticonazole + tinidazole + lidocaine formulations against Gynomax® XL ovule for bacterial vaginosis, candidal vulvovaginitis, trichomonal vaginitis and mixed infections; not a tioconazole-specific trial |
Note: Neither registered trial evaluates tioconazole directly; both provide indirect, disease-level supporting context rather than drug-specific confirmatory evidence.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3524439 | 1986 | RCT | Antimicrobial Agents and Chemotherapy | Single-dose 6.5% tioconazole ointment achieved cure rates comparable to 3-day clotrimazole (84% vs 85%) in vulvovaginal candidiasis |
| 6347833 | 1983 | RCT | Gynäkologische Rundschau | Double-blind comparison of tioconazole vs placebo in vaginal candidiasis, with assessment of systemic absorption |
| 6094282 | 1984 | RCT | The Journal of International Medical Research | Single-dose topical tioconazole 6% vaginal ointment vs 5-day oral ketoconazole; both eradicated infection, topical arm had faster symptom relief |
| 3510114 | 1986 | Review | Drugs | Comprehensive review confirming broad-spectrum antifungal activity and established efficacy of topical tioconazole in vaginal candidiasis |
| 40464716 | 2025 | Review | Expert Review of Anti-infective Therapy | Reviews non-invasive azole treatment options for vulvovaginal candidiasis, confirming continued clinical relevance of topical azoles |
| 10470518 | 1999 | Review | Comprehensive Therapy | Reviews epidemiology, diagnosis and therapy of vulvovaginitis in otherwise healthy women |
| 34550113 | 2021 | Review | The Medical Letter on Drugs and Therapeutics | Drug evaluation bulletin on ibrexafungerp for vulvovaginal candidiasis, contextualising topical azole alternatives |
| 6347834 | 1983 | Cohort/Open-label | Gynäkologische Rundschau | Open comparison of tioconazole vs econazole over 3-day treatment showing comparable efficacy and tolerability |
| 6873744 | 1983 | Case series | Gynäkologische Rundschau | Open comparison of tioconazole cream vs econazole ovules in 3-day treatment of vaginal candidiasis |
| 3485546 | 1986 | Case series | The Journal of International Medical Research | Open non-comparative study of 2% tioconazole vaginal cream in Trichomonas vaginalis and mixed vaginal infections; 95% cure rate at follow-up |
UK Market Information
Tioconazole currently holds no active marketing authorisation in the UK (market status: Not marketed; 0 registered licences in this Evidence Pack). No MHRA product listing or BNF entry is available for cross-reference. Historically, tioconazole has been marketed in other jurisdictions (e.g. as vaginal ointment/cream and nail lacquer formulations for candidal vulvovaginitis and onychomycosis), but no equivalent UK-authorised product is on record here.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple historical randomised and open comparative studies support tioconazole’s efficacy against candidal vaginal infection, which is mechanistically and clinically consistent with vulvovaginitis. However, neither registered clinical trial tests tioconazole directly, the drug has no current UK marketing authorisation, and this Evidence Pack lacks MOA and safety labelling data, so guardrails are required before any advancement.
To proceed, the following is needed:
- MHRA/SmPC safety labelling (key warnings, contraindications, drug interactions) — currently a Blocking data gap
- Confirmed mechanism of action data via DrugBank — currently a High-severity data gap
- Confirmation of tioconazole’s identity/route within the two registered trials, since both currently test other or combination formulations
- Assessment of UK market re-entry feasibility given “Not marketed” status and zero active licences
- Route compatibility data (available vs required administration routes for vulvovaginitis treatment)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.